Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11290619 | 0.95 | LMNA (0.53) | LMNAMAPTABCB11MAPK1EPHX2 | |
| SCHEMBL11289971 | 0.89 | LMNA (0.58) | LMNAMAPTABCB11MAPK1POLB | |
| SCHEMBL11289940 | 0.88 | LMNA (0.57) | LMNAMAPTABCB11MAPK1L3MBTL1 | |
| SCHEMBL11268538 | 0.85 | LMNA (0.58) | LMNAMAPTABCB11MAPK1L3MBTL1 | |
| SCHEMBL11268263 | 0.85 | LMNA (0.58) | LMNAMAPTABCB11MAPK1L3MBTL1 | |
| SCHEMBL11266263 | 0.85 | LMNA (0.58) | LMNAMAPTABCB11MAPK1L3MBTL1 | |
| SCHEMBL11275748 | 0.85 | LMNA (0.58) | LMNAMAPTABCB11MAPK1L3MBTL1 | |
| SCHEMBL11293789 | 0.84 | LMNA (0.52) | LMNAMAPTABCB11MAPK1L3MBTL1 | |
| SCHEMBL11292121 | 0.84 | MAPT (0.78) | LMNAMAPTABCB11MAPK1TDP1 | |
| SCHEMBL957321 | 0.84 | MAPT (0.78) | LMNAMAPTABCB11MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | HORST P.O. WOLF (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6013666-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | Jew, Sang Sup (KR) | 2000-01-11 | — | — | US | disclosed |
| WO-1998000422-A1 | OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD | JEW SANG SUP (KR) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | GPR119, SLC5A2, SLC2A4 | LMNA 3609/4885MAPT 4759/4885ABCB11 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.